Skip to main content
Logo Mark
Search Icon
Geron
  • Research & Development
    • Telomerase Inhibition
    • Imetelstat
    • Publications
    • Clinical Trials
    • Healthcare Professionals
  • Patients
  • Investors & Media
    • Press Releases
    • Events
    • Stock Information
    • Corporate Governance
    • SEC Filings
    • Analyst Coverage
    • FAQs
  • About
    • Leadership
    • Culture
    • History
    • Contact
  • Careers

Publications

Filter by:

Featured

Imetelstat Achieved Prolonged, Continuous Transfusion Independence in Patients With Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory to Erythropoiesis Stimulating Agents Within the IMerge Phase 2 Study

Clinical Imetelstat: MDSImetelstat
ASH 2022

Platzbecker, et al.


Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia

ImetelstatNon-clinical Imetelstat
ASH 2022

Bruedigam C, et al.



All

    MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

    Clinical Imetelstat: MFImetelstat
    ASH 2022

    Mascarenhas, et al.


    An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate-1, Intermediate-2 or High-Risk Myelofibrosis

    Clinical Imetelstat: MFImetelstat
    ASH 2022

    Bradley T, et al.


    Imetelstat Achieved Prolonged, Continuous Transfusion Independence in Patients With Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory to Erythropoiesis Stimulating Agents Within the IMerge Phase 2 Study

    Clinical Imetelstat: MDSImetelstat
    ASH 2022

    Platzbecker, et al.


    Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia

    ImetelstatNon-clinical Imetelstat
    ASH 2022

    Bruedigam C, et al.


    Pharmacological Inhibitory Effect of Imetelstat, A Novel Human Telomerase Inhibitor in Diffuse Large B-cell Lymphoma and Peripheral T-Cell Lymphoma

    ImetelstatNon-clinical Imetelstat
    Blood 2022

    Aradhya A, et al.


    Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design

    Clinical Imetelstat: MFImetelstat
    Future Oncology 2022

    Mascarenhas, et al.


    Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts

    ImetelstatNon-clinical Imetelstat
    Journal of Clinical Medicine 2022

    Barwe, et al.


    The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes

    Relevant MF Publications
    Cancer 2022

    Mascarenhas, et al.


    Clinical and biological characterization of Low Risk MDS patients according to Ring Sideroblasts (RS). Comparison between the 3 subgroups in WHO2017 classification. Study from the Spanish MDS registry

    Relevant MDS Publications
    ASH 2021

    Cadenas FL, et al.


    Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data

    Clinical Imetelstat: MFImetelstat
    Annals of Hematology 2021

    Kuykendall, et al.


    Efficacy of Imetelstat is Independent of Molecular Subtypes in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESA)

    Clinical Imetelstat: MDSImetelstat
    EHA 2021

    Platzbecker, et al.


    Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

    Clinical Imetelstat: MFImetelstat
    Journal of Clinical Oncology 2021

    Mascarenhas, et al.


    Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study

    Clinical Imetelstat: MDSImetelstat
    Journal of Clinical Oncology 2020

    Steensma, et al.


    Imetelstat Demonstrates an Acceptable Safety Profile in Myeloid Malignancies

    Clinical Imetelstat: MDSImetelstat
    EHA 2021

    Mascarenhas, et al.


    Current challenges and unmet needs in myelodysplastic syndromes

    Relevant MDS Publications
    Leukemia 2021

    Platzbecker, et al.



Patients

We are on a mission to improve and extend lives

Discover more about our commitment to patients


Learn more
Explore
  • Research & Development
  • Pipeline
  • Partnering
  • Patients
Browse
  • Latest updates
  • Publications
  • Corporate profile
  • Press releases
  • Events
Learn
  • About
  • Leadership
  • Culture
  • History
Connect
  • Careers
  • Locations
  • Contacts
Follow
LinkedIn
Geron
  • Terms of Use
  • Privacy Policy
  • Cookie Policy

Copyright © 2023 Geron. All rights reserved

Back to top